Product category:
Chemicals and biochemicals
News Release from: Frost and Sullivan
Edited by the Laboratorytalk Editorial
Team on 22 July 2002
Perspective on Pfizer and Pharmacia
Analyst comment on the Pfizer acquisition of Pharmacia by Imran Khalifa, industry manager pharmaceuticals, Frost and Sullivan
Pfizer's acquisition of Pharmacia for nearly $60 billion in stock has created the largest pharmaceutical company in the world with annual revenues of $48 billion This acquisition comes at a time when the pharmaceuticals and biotech companies are under increased scrutiny and are facing unprecedented challenges
This article was originally published on Laboratorytalk on 2 Aug 2002 at 8.00am (UK)
Related stories
Smart materials: the new frontier of technology
Analysis reveals the advances made in the development of industrial applications for smart, active, or engineered materials, including their use in smart structures
Ready for convergence?
The convergence of nanotechnology, biotechnology, information technology, and cognitive science will have a substantial impact on companies and markets in the future
The general public is clamouring for reduced drug prices, and the general malaise affecting corporate America has sparked a closer watch from regulatory authorities.
On the other hand, most major pharmaceutical companies have become saddled with declining research productivity, directly affecting their product pipeline.
With the patent expiry of several billion dollar blockbusters looming large, companies are increasingly desperate to meet the impending shortfall in revenues due to the generic invasion.
Further reading
European cardiac risk assessment markers
Elevated European CHF mortality rates and introduction of premium-priced assays stimulate uptake of cardiac risk assessment markers, according to new research
Bubble bursts in defoamer market
Negative growth will force European pulp and paper defoamer suppliers to recognise commodity market, says new report
From the long-term strategic point of view, this deal makes sense.
The greatest gain for Pfizer would probably be in anti-cancer therapeutics, where it has a minimal presence.
Pharmacia's colorectal cancer product, Camptosar, has been one of the few success stories in the oncology area in the past few years.
This product was the cornerstone of the oncology franchise, with expanded indications expected in lung cancer and other solid tumours.
There are other promising anti-cancer products in phase III trials.
The combined Pfizer-Pharmacia new product pipeline would have almost 200 candidates, with an annual R and D spending to the tune of $7 billion.
This acquisition has also changed the competitive landscape of the industry, with Pfizer becoming the largest pharmaceutical company in the world.
Recently, most of the attention was centered on the possibility of Bristol-Myers Squibb being a take-over candidate for a larger pharmaceutical company, with GlaxoSmithKline (GSK) being in the forefront.
This new scenario places renewed pressure on GSK, the erstwhile number one, to catch-up with Pfizer with an acquisition of its own.
Finally, Fred Hassan, the chairman and CEO of Pharmacia and vice-chairman and director in the newly formed Pfizer, is renowned for the successful implementation of mergers and acquisitions.
His last merger of Pharmacia and Upjohn with Monsanto to create Pharmacia Corporation was smooth and completed in record time.
Hence, Pfizer has gained access to an individual known for his expertise in ensuring a smooth transformation.
Pfizer's acquisition of Pharmacia has set the pace, and it's now time for the industry to catch up.
• Frost and Sullivan: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
